BiotechTube

VB10.16 + Pembrolizumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Conditions

HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC

Trial Timeline

Dec 19, 2023 → Jan 1, 2028

NCT ID
NCT06016920

About VB10.16 + Pembrolizumab

VB10.16 + Pembrolizumab is a phase 1/2 stage product being developed by Merck for HPV Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06016920. Target conditions include HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC.

What happened to similar drugs?

9 of 20 similar drugs in HPV Positive Oropharyngeal Squamous Cell Carcinoma were approved

Approved (9) Terminated (2) Active (10)
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
✅GefitinibAstraZenecaApproved
✅ceritinibNovartisApproved
✅NilotinibNovartisApproved
✅AsciminibNovartisApproved
✅RAD001 + ExemestaneNovartisApproved
✅Trastuzumab emtansineRocheApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06016920Phase 1/2Recruiting

Competing Products

20 competing products in HPV Positive Oropharyngeal Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
23
CT-0525Carisma TherapeuticsPhase 1
23
TrastuzumabCelltrionPhase 3
40
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
YH32367YuhanPhase 1/2
39
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
44
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
ASP0113 + PlaceboAstellas PharmaPhase 3
40
IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)Astellas PharmaPhase 1
29
EnzalutamideAstellas PharmaPhase 2
35
ASP1893Astellas PharmaPhase 1
21